» Articles » PMID: 32986710

NOD2 Receptor is Crucial for Protecting Against the Digestive Form of Chagas Disease

Abstract

Digestive and cardiodigestive forms of Chagas' disease are observed in 2% to 27% of the patients, depending on their geographic location, Trypanosoma cruzi strain and immunopathological responses. The aim of this work was to evaluate the role of NOD2 innate immune receptor in the pathogenesis of the digestive system in Chagas' disease. Patients with digestive form of the disease showed lower mRNA expression of NOD2, higher expression of RIP2 and α-defensin 6, compared to indeterminate form, detected by Real-time PCR in peripheral blood mononuclear cells. In addition, there was a negative correlation between the expression of NOD2 and the degree of dilation of the esophagus, sigmoid and rectum in those patients. The infection of NOD2-/- mice with T. cruzi strain isolated from the digestive patient induced a decrease in intestinal motility. Histopathological analysis of the colon and jejunum of NOD2-/- and wild type C57BL/6 animals revealed discrete inflammatory foci during the acute phase of infection. Interestingly, during the chronic phase of the infection there was inflammation and hypertrophy of the longitudinal and circular muscular layer more pronounced in the colon and jejunum from NOD2-/- animals, when compared to wild type C57BL/6 mice. Together, our results suggest that NOD2 plays a protective role against the development of digestive form of Chagas' disease.

Citing Articles

Animal models for exploring Chagas disease pathogenesis and supporting drug discovery.

Khan A, Taylor M, Fortes Francisco A, Jayawardhana S, Atherton R, Olmo F Clin Microbiol Rev. 2024; 37(4):e0015523.

PMID: 39545730 PMC: 11629624. DOI: 10.1128/cmr.00155-23.


Neuroprotective Treatments for Digestive Forms of Chagas Disease in Experimental Models: A Systematic Review.

Rodrigues do Carmo Neto J, Guerra R, Rodrigues W, da Silva M, Machado J Oxid Med Cell Longev. 2022; 2022:9397290.

PMID: 36199427 PMC: 9527410. DOI: 10.1155/2022/9397290.


Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review.

Medina-Rincon G, Gallo-Bernal S, Jimenez P, Cruz-Saavedra L, Ramirez J, Rodriguez M Pathogens. 2021; 10(11).

PMID: 34832648 PMC: 8619182. DOI: 10.3390/pathogens10111493.


Correlation between intestinal BMP2, IFNγ, and neural death in experimental infection with Trypanosoma cruzi.

Rodrigues do Carmo Neto J, da Silva M, Braga Y, da Costa A, Fonseca S, Nagib P PLoS One. 2021; 16(2):e0246692.

PMID: 33561140 PMC: 7872263. DOI: 10.1371/journal.pone.0246692.

References
1.
de Oliveira G, de Melo Medeiros M, Batista W, Santana R, Araujo-Jorge T, Pereira de Souza A . Applicability of the use of charcoal for the evaluation of intestinal motility in a murine model of Trypanosoma cruzi infection. Parasitol Res. 2007; 102(4):747-50. DOI: 10.1007/s00436-007-0829-8. View

2.
Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M . NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004; 53(11):1658-64. PMC: 1774270. DOI: 10.1136/gut.2003.032805. View

3.
Sanchez-Munoz F, Fonseca-Camarillo G, Villeda-Ramirez M, Miranda-Perez E, Mendivil E, Barreto-Zuniga R . Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol. 2011; 11:138. PMC: 3287145. DOI: 10.1186/1471-230X-11-138. View

4.
Andrade C, da Camara A, Nunes D, da Matta Guedes P, Pereira W, Chiari E . Chagas disease: morbidity profile in an endemic area of Northeastern Brazil. Rev Soc Bras Med Trop. 2015; 48(6):706-15. DOI: 10.1590/0037-8682-0235-2015. View

5.
Oliveira A, Peixoto J, Arruda L, Campos M, Gazzinelli R, Golenbock D . Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol. 2004; 173(9):5688-96. DOI: 10.4049/jimmunol.173.9.5688. View